Acorda Therapeutics

Acorda Therapeutics, Inc. engages in the development of therapies that restore function and improve the lives of people with neurological disorders. Its products include Inbrija (levodopa inhalation powder), Ampyra (dalfampridine), Fampyra (fampridine) and Selincro (nalmefene). The firm's also offers Research and Development Programs like ARCUS for acute migraine, Cimaglermin alfa and rHIgM22. The company was founded by Ronald Cohen in 1995 and is headquartered in Ardsley, NY.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Global Ecology Corp. engages in the development, production and marketing of advanced waste remediation technologies that address universal environmental issues, which include organic soil revitalization, reduction of greenhouse gas emissions, solid waste remediation and point-of-use water purification solutions. The company was founded in 1993 and is headquartered in Las Vegas, NV.

Acorda (ACOR) posts narrower-than-expected loss while revenues top estimates in the second quarter. Inbrija delivers a solid start with sales rising sequentially.

Acorda (ACOR) Q2 Earnings and Revenues Surpass Estimates

Acorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q2 2019 Results - Earnings Call Transcript

On Acorda's (ACOR) second-quarter earnings call, investor focus will be on the sales uptick of its newly launched Parkinson's disease drug Inbrija.

Acorda (ACOR) to Post Q2 Earnings: What's in the Cards?

Acorda (ACOR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Acorda Therapeutics (ACOR) to Report a Decline in Earnings: What to Look Out for

In the latest trading session, Acorda Therapeutics (ACOR) closed at $6.82, marking a +0.89% move from the previous day.

Acorda Therapeutics (ACOR) Outpaces Stock Market Gains: What You Should Know

Acorda Therapeutics has had a difficult year with the genericization of their AMPYRA asset in September 2018.

Acorda Oversold: Runway To Positive Cash Flow

Acorda (ACOR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About Acorda (ACOR) Rating Upgrade to Buy

Arena (ARNA) doses first patient in one of the two pivotal late-stage studies evaluating its pipeline candidate, etrasimod in ulcerative colitis indication.

Arena Initiates Dosing in Pivotal Colitis Study on Etrasimod

Acorda (ACOR) reported earnings 30 days ago. What's next for the stock?

Acorda (ACOR) Down 11.3% Since Last Earnings Report: Can It Rebound?

Incyte

Mesoblast

Repligen

Mesoblast (MESO) begins the rolling submission of a BLA for its lead product, candidate remestemcel-L, to the FDA for treating children with steroid-refractory acute graft versus host disease.

Mesoblast Starts Rolling BLA Submission for Remestemcel-L

Acorda Therapeutics' (ACOR) CEO Ron Cohen on Q1 2018 Results - Earnings Call Transcript

Acorda's (ACOR) shares rise on earnings and revenue beat in Q1. Inbrija registers first sales figure following its launch in the reported quarter.

Acorda (ACOR) Earnings and Revenues Beat Estimates in Q1

Earnings Preview: Acorda Therapeutics (ACOR) Q1 Earnings Expected to Decline

Acorda (ACOR) aims to boost sales with the launch of its newly FDA-approved Parkinson's disease drug, Inbrija. The company's pipeline looks promising as well.

News for Acorda Therapeutics Stock (ACOR)